Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Rhea-AI Summary

Cognition Therapeutics (NASDAQ: CGTX) announced that CEO Lisa Ricciardi will present at the virtual Zacks SCR Life Sciences Investor Forum on November 14, 2024, at 11:00 a.m. ET. The presentation will highlight results from the successful Phase 2 'SHINE' study of CT1812 in Alzheimer's disease and provide updates on ongoing clinical programs, including the Phase 2 'SHIMMER' study in dementia with Lewy bodies. Topline results from 'SHIMMER' are expected by year-end 2024.

The live, interactive event will allow real-time Q&A with management. An archived webcast will be available on Cognition's Investor Relations webpage for those unable to attend live. Pre-registration is recommended for interested investors.

PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that President and CEO Lisa Ricciardi will present live at the virtual Zacks SCR Life Sciences Investor Forum on November 14, 2024. The Company’s presentation will focus primarily on the results from the successful Phase 2 ‘SHINE’ study of CT1812 in mild-to-moderate Alzheimer’s disease. In addition, Ms. Ricciardi will provide an overview of the Company’s ongoing clinical programs, including the Phase 2 ‘SHIMMER’ study of CT1812 in dementia with Lewy bodies. Topline results from the ‘SHIMMER’ study are expected by year-end 2024.

This will be a live, interactive, online event. Members of the management team will be available to answer questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will be made available on Cognition’s Investor Relations webpage. It is recommended that investors interested in attending the live event pre-register to expedite their participation and receive event updates.

Presentation Details:
Life Sciences Investor Forum
Date/time: November 14, 2024 at 11:00 a.m. Eastern Time
Location: Virtual
To register, please visit www.virtualinvestorconferences.com.

About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com 

About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Global Market and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 

Contact Information:    Cognition Therapeutics, Inc. info@cogrx.com

Casey McDonald (media)  Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com

Mike Moyer (investors) LifeSci Advisors  mmoyer@lifesciadvisors.com

This press release was published by a CLEAR® Verified individual.

FAQ

When will Cognition Therapeutics (CGTX) present at the Zacks SCR Life Sciences Investor Forum?

Cognition Therapeutics will present on November 14, 2024, at 11:00 a.m. Eastern Time during the virtual Zacks SCR Life Sciences Investor Forum.

What clinical trial results will CGTX discuss at the Zacks investor forum?

CGTX will discuss results from the Phase 2 'SHINE' study of CT1812 in mild-to-moderate Alzheimer's disease and provide updates on the Phase 2 'SHIMMER' study in dementia with Lewy bodies.

When will CGTX release topline results for the SHIMMER study?

Cognition Therapeutics expects to release topline results from the Phase 2 'SHIMMER' study by year-end 2024.

How can investors attend CGTX's presentation at the Zacks forum?

Investors can attend by registering at www.virtualinvestorconferences.com. The event will be held virtually, and an archived webcast will be available on Cognition's Investor Relations webpage.